Faricimab for wet AMD with subretinal material
Part of Eyes & vision clinical trials.
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older.
- You have age-related macular degeneration (AMD) in both eyes or one eye.
- You have a specific type of abnormal blood vessel growth called 'type 2' or 'mixed (type 1 and 2)' neovascular membrane, and also have subretinal hyper-reflective material (SHRM) – a sign of fluid or debris under the retina.
- You have not been treated with Faricimab (Vabysmo) before in the eye that will be studied.
- You do not have other serious eye diseases (like diabetic retinopathy or severe near-sightedness) that could affect your vision, and you are not pregnant, breastfeeding, or planning to become pregnant.
- You agree to participate and sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
This trial tests a new eye drop-free injection medication called faricimab for people with wet age-related macular degeneration who haven't improved enough on standard anti-VEGF shots. The goal is to see if it can reduce fluid and improve vision better than usual treatments.
This study observes the effects of a drug called faricimab (given as eye injections) on people with wet age-related macular degeneration (AMD), a condition causing rapid vision loss from abnormal blood vessels leaking fluid in the back of the eye. It aims to see how well the drug works when given in a specific schedule and to monitor safety and outcomes over time. This is an observational study, so you would receive the treatment as part of your normal care, and the research team will collect data.
This study tests a medication called faricimab, given as eye injections over a long period, for people with a specific type of wet age-related macular degeneration. The goal is to see if this treatment can help maintain or improve vision over time.
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
Hear when a new Macular Degeneration, Age Related trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.